VIJAYA - Vijaya Diagnostic Centre Limited Share Price

Management's outlook for Vijaya Diagnostic Centre Limited is optimistic, highlighting a record quarterly revenue of approximately INR 205 crores for Q3 FY '26, representing a year-on-year growth of 21.4%. This growth is attributed to a 15% increase in test volume, showcasing the company's robust performance. The strong demand is driven by their pathology and radiology segments, with significant contributions from the Wellness sector as well.

Key forward-looking points include:

1. Expansion Plans: The company aims to continue network expansion, commissioning 4 to 5 new hubs and 10 to 12 spokes in FY '27. This strategy will focus on stabilizing newly launched hubs and enhancing customer experience through technology.

2. Financial Performance: For the nine months ending December 31, 2025, consolidated revenue reached INR 595 crores, an increase of 17.1% year-on-year, with a healthy EBITDA margin of 40.6%. The profit after tax for Q3 stood at INR 43 crores, showing a growth of 22.3%.

3. Hub Performance: New hubs, particularly in West Bengal and the core markets of Khammam and Nandyal, have ramped up steadily, achieving breakeven ahead of expectations, typically within one year.

4. Wellness Segment Growth: The Wellness segment has seen significant growth due to rising health consciousness, contributing nearly 15% of total revenue. Management believes this can exceed 20% moving forward.

5. Cost Management: The company has reported a net surplus cash of INR 260 crores as of December 31, positioning them well for future capital expenditure and potential M&A opportunities.

The outlook reflects confidence in maintaining margins around 40%, despite ongoing investments in technology and talent aimed at fostering long-term sustainable growth.

Major Questions and Answers from the Earnings Transcript

Q1: "Could you quantify the growth in the Hyderabad market on a Y-on-Y basis?"
A: "The growth in the Hyderabad market was close to 15% on a Y-o-Y basis, equally driven by pathology and radiology."

Q2: "Would you be able to allude as to what has caused this strong growth in the core region?"
A: "The favorable season for pathology and spillover from Q2 contributed to strong growth, alongside pre-festive demand."

Q3: "What could be the steady state of hub expansion over the next 2 to 3 years?"
A: "In FY '27, we plan to add 4-5 hubs and 10-12 spokes. For FY '28 and '29, an optimal mix of hubs and spokes is expected."

Q4: "What would be the net cash position as on December?"
A: "The net surplus cash as of December 31 is INR 260 crores, with total cash around INR 305 crores."

Q5: "What is your M&A strategy going ahead?"
A: "We're always open to M&A if the right asset is available, focusing on B2C geography. No current acquisitions are planned."

Q6: "What impact do you foresee on input costs due to dollar fluctuation and GST changes?"
A: "We expect minimal impact from fluctuations. Long-term contracts for reagents shield us from price volatility, balanced by GST benefits."

Q7: "How do you see growth levers for Q4 given seasonal impacts?"
A: "Historically, we expect to surpass 15% growth in Q4, driven by wellness segment growth and an uptick in corporate packages."